Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Jan. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Eczema Therapeutics market. The report identifies the key trends shaping and driving the global Eczema Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Eczema Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Eczema Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Eczema Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Eczema Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Eczema Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Eczema Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Eczema Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Eczema Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Eczema Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Eczema Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Symptoms 10
2.5 Diagnosis 10
2.6 Pathophysiology 11
2.7 Treatment and Management Pattern 12
2.8 GlobalData Pipeline Report Guidance 16
3 EczemaTherapeutics - Market Characterization 17
3.1 Eczema Therapeutics Market Size (2005-2010) - Global 17
3.2 Eczema Therapeutics Market Forecast (2010-2018) - Global 18
3.3 Eczema Therapeutics Market Size (2005-2010) - The US 19
3.4 Eczema Therapeutics Market Forecast (2010-2018) - The US 20
3.5 Eczema Therapeutics Market Size (2005-2010) - France 21
3.6 Eczema Therapeutics Market Forecast (2010-2018) - France 22
3.7 Eczema Therapeutics Market Size (2005-2010) - Germany 23
3.8 Eczema Therapeutics Market Forecast (2010-2018) - Germany 24
3.9 Eczema Therapeutics Market Size (2005-2010) - Italy 25
3.10 Eczema Therapeutics Market Forecast (2010-2018) - Italy 26
3.11 Eczema Therapeutics Market Size (2005-2010) - Spain 27
3.12 Eczema Therapeutics Market Forecast (2010-2018) - Spain 28
3.13 Eczema Therapeutics Market Size (2005-2010) - The UK 29
3.14 Eczema Therapeutics Market Forecast (2010-2018) - The UK 30
3.15 Eczema Therapeutics Market Size (2005-2010) - Japan 31
3.16 Eczema Therapeutics Market Forecast (2010-2018) - Japan 32
3.17 Drivers and Barriers for the Eczema Market 33
3.17.1 Drivers for the Eczema Therapeutics Market 33
3.17.2 Barriers for the Eczema Therapeutics Market 33
3.18 Opportunity and Unmet Need 34
3.19 Key Takeaway 34
4 Eczema Therapeutics Market - Competitive Assessment 35
4.1 Overview 35
4.2 Strategic Competitor Assessment 36
4.3 Product Profile for Major Marketed Products in the Eczema Therapeutics Market 36
4.3.1 Protopic (tacrolimus) 36
4.3.2 Elidel (pimecrolimus) 37
4.3.3 MimyX 40
4.3.4 Atopiclair 40
4.3.5 Topical Corticosteroids 41
4.4 Key Takeaway 42
5 Eczema Therapeutics - Pipeline Assessment 43
5.1 Overview 43
5.2 Strategic Pipeline Assessment 43
5.3 Eczema Therapeutics - Pipeline Analysis by Phase of Development 43
5.3.1 Eczema Therapeutics - Filed and Phase III Pipeline 43
5.3.2 Eczema Therapeutics - Phase II Pipeline 44
5.3.3 Eczema Therapeutics - Phase I Pipeline 45
5.3.4 Eczema Therapeutics - Preclinical Pipeline 45
5.4 Eczema Therapeutics - Pipeline by Mechanism of Action 46
5.5 Technology Trends Analytical Framework 48
5.6 Most Promising Drug Profiles 49
5.6.1 LAS 41002 49
5.7 Key Takeaway 50
6 Eczema Therapeutics - Clinical Trials Mapping 51
6.1 Clinical Trials by Region and Country 51
6.2 Clinical Trials by Phase of Clinical Development 52
6.3 Clinical Trials by Trial Status 53
6.4 Clinical Trials by Sponsors 54
6.5 Top Companies Participating in Eczema Clinical Trials 56
7 Eczema Therapeutics Market - Strategic Assessment 57
7.1 Key Events Impacting the Future Market 57
7.2 Future Market Competition Scenario 57
8 Eczema Therapeutics Market - Future Players 59
8.1 Introduction 59
8.2 Company Profiles 59
8.2.1 Almirall 59
8.2.2 Anacor Pharmaceuticals 60
8.2.3 BioCis Pharmaceuticals 61
8.2.4 MIKA Pharma GmbH 61
8.2.5 Novartis AG 62
8.2.6 GlaxoSmithKline 63
8.2.7 Sanofi 65
8.3 Details of Other Companies in the Pipeline 67
8.4 Key Takeaway 67
9 Eczema Therapeutics - Licensing and Partnership Deals 68
10 Eczema Therapeutics - Appendix 70
10.1 Definitions 70
10.2 Acronyms 70
10.3 Research Methodology 71
10.3.1 Coverage 72
10.3.2 Secondary Research 72
10.3.3 Forecasting 72
10.3.4 Primary Research 75
10.3.5 Expert Panel Validation 75
10.4 Contact Us 75
10.5 Disclaimer 75
10.6 Bibliography 76
List of Tables
Table 1: Eczema Therapeutics - Treatment Options 13
Table 2: Eczema Therapeutics - Commonly Used Topical Corticosteroids 13
Table 3: Eczema Therapeutics Market, Global, Revenue ($m), 2005-2010 17
Table 4: Eczema Therapeutics Market, Global, Forecast ($m), 2010-2018 18
Table 5: Eczema Therapeutics Market, The US, Revenue ($m), 2005-2010 19
Table 6: Eczema Therapeutics Market, The US, Forecast ($m), 2010-2018 20
Table 7: Eczema Therapeutics Market, France, Revenue ($m), 2005-2010 21
Table 8: Eczema Therapeutics Market, France, Forecast ($m), 2010-2018 22
Table 9: Eczema Therapeutics Market, Germany, Revenue ($m), 2005-2010 23
Table 10: Eczema Therapeutics Market, Germany, Forecast ($m), 2010-2018 24
Table 11: Eczema Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Table 12: Eczema Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Table 13: Eczema Therapeutics Market, Spain, Revenue ($m), 2005-2010 27
Table 14: Eczema Therapeutics Market, Spain, Forecast ($m), 2010-2018 28
Table 15: Eczema Therapeutics Market, The UK, Revenue ($m), 2005-2010 29
Table 16: Eczema Therapeutics Market, The UK, Forecast ($m), 2010-2018 30
Table 17: Eczema Therapeutics Market, Japan, Revenue ($m), 2005-2010 31
Table 18: Eczema Therapeutics Market, Japan, Forecast ($m), 2010-2018 32
Table 19: Eczema Therapeutics Market, Global, Comparative Study on the Efficacy of Protopic in Phase III Clinical Trials, 2003 37
Table 20: Eczema Therapeutics - Efficacy Assessment 38
Table 21: Eczema Therapeutics Market, Global, Comparative Study on the Efficacy of Elidel in Clinical Trials, 1998-2002 39
Table 22: Eczema Therapeutics Market, Global, Major Marketed Products Comparison, 2011 42
Table 23: Eczema Therapeutics - Filed and Phase III Clinical Pipeline, 2011 43
Table 24: Eczema Therapeutics - Phase II Clinical Pipeline, 2011 44
Table 25: Eczema Therapeutics - Phase I Clinical Pipeline, 2011 45
Table 26: Eczema Therapeutics - Preclinical and Discovery Pipeline, 2011 45
Table 27: LAS 41002 - Clinical Study Details 50
Table 28: Eczema Therapeutics, Global, Clinical Trials by Country, 2011 51
Table 29: Eczema Therapeutics, Global, Clinical Trials by Phase, 2011 52
Table 30: Eczema Therapeutics, Global, Clinical Trials by Status of Development, 2011 53
Table 31: Eczema Therapeutics, Global, Overall Sponsors, 2011 54
Table 32: Eczema Therapeutics, Global, Prominent Sponsors, 2011 55
Table 33: Eczema Therapeutics, Global, Top Ten Companies by Phase, 2011 56
Table 34: Almirall - Dermatology Pipeline Products, 2011 60
Table 35: Anacor Pharmaceuticals - Dermatology Pipeline Products, 2011 60
Table 36: BioCis Pharmaceuticals - Dermatology Pipeline Products, 2011 61
Table 37: MIKA Pharma GmbH - Dermatology Pipeline Products, 2011 61
Table 38: Novartis AG - Dermatology Pipeline Products, 2011 63
Table 39: GlaxoSmithKline - Dermatology Pipeline Products, 2011 64
Table 40: Sanofi - Dermatology Pipeline Products, 2011 66
Table 41: Description of Other Companies in the Pipeline, 2011 67
Table 42: Eczema Therapeutics, Global, Deals, 2011 68
List of Figures
Figure 1: Eczema Therapeutics - Eczematous Skin 7
Figure 2: Clinical Classification of Eczema 7
Figure 3: Eczema Therapeutics - Types of Eczema 8
Figure 4: Eczema Therapeutics - Atopic Triad 9
Figure 5: Eczema - Triggers of Itch 9
Figure 6: Eczema - Sign and Symptoms 10
Figure 7: Eczema - Pathophysiology 11
Figure 8: Eczema - Treatment Algorithm 14
Figure 9: Eczema - Treatment Selection Chart 15
Figure 10: Eczema Therapeutics Market, Global, Revenue ($m), 2005-2010 17
Figure 11: Eczema Therapeutics Market, Global, Forecast ($m), 2010-2018 18
Figure 12: Eczema Therapeutics Market, The US, Revenue ($m), 2005-2010 19
Figure 13: Eczema Therapeutics Market, The US, Forecast ($m), 2010-2018 20
Figure 14: Eczema Therapeutics Market, France, Revenue ($m), 2005-2010 21
Figure 15: Eczema Therapeutics Market, France, Forecast ($m), 2010-2018 22
Figure 16: Eczema Therapeutics Market, Germany , Revenue ($m), 2005-2010 23
Figure 17: Eczema Therapeutics Market, Germany, Forecast ($m), 2010-2018 24
Figure 18: Eczema Therapeutics Market, Italy, Revenue ($m), 2005-2010 25
Figure 19: Eczema Therapeutics Market, Italy, Forecast ($m), 2010-2018 26
Figure 20: Eczema Therapeutics Market, Spain, Revenue ($m), 2005-2010 27
Figure 21: Eczema Therapeutics Market, Spain, Forecast ($m), 2010-2018 28
Figure 22: Eczema Therapeutics Market, The UK, Revenue ($m), 2005-2010 29
Figure 23: Eczema Therapeutics Market, The UK, Forecast ($m), 2010-2018 30
Figure 24: Eczema Therapeutics Market, Japan, Revenue ($m), 2005-2010 31
Figure 25: Eczema Therapeutics Market, Japan, Forecast ($m), 2010-2018 32
Figure 26: Opportunity and Unmet Need in the Eczema Therapeutics Market, 2011 34
Figure 27: Strategic Competitor Assessment of the Marketed Products in Eczema Therapeutics, 2011 35
Figure 28: Eczema Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 46
Figure 29: Eczema - Clinical Pipeline by Phase of Development (%), 2011 47
Figure 30: Technology Trends Analytics Framework, 2011 48
Figure 31: Technology Trends Analytics Framework - Description, 2011 48
Figure 32: Eczema Therapeutics, Global, Clinical Trials by Country, 2011 51
Figure 33: Eczema Therapeutics, Global, Clinical Trials by Phase (%), 2011 52
Figure 34: Eczema Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 53
Figure 35: Eczema Therapeutics, Global, Overall Sponsors (%), 2011 54
Figure 36: Eczema Therapeutics, Global, Prominent Sponsors (%), 2011 55
Figure 37: Eczema Therapeutics, Global, Top Companies by Phase, 2011 56
Figure 38: Eczema Therapeutics Market, Drivers and Barriers, 2011 57
Figure 39: Implications for Future Market Competition in the Eczema Therapeutics Market, 2011 57
Figure 40: Eczema Therapeutics Market, Clinical Pipeline by Company, 2011 59
Figure 41: GlobalData Market Forecasting Model 74
Companies mentioned
Almirall
Anacor Pharmaceuticals
BioCis Pharmaceuticals
MIKA Pharma GmbH
Novartis AG
GlaxoSmithKline
Sanofi
To order this report:
Therapy Industry: Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article